CWA Asset Management Group LLC Makes New Investment in InMode Ltd. (NASDAQ:INMD)

CWA Asset Management Group LLC acquired a new stake in shares of InMode Ltd. (NASDAQ:INMD) during the 4th quarter, Holdings Channel reports. The firm acquired 21,961 shares of the healthcare company’s stock, valued at approximately $367,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Systematic Financial Management LP increased its position in InMode by 13.3% in the 3rd quarter. Systematic Financial Management LP now owns 982,111 shares of the healthcare company’s stock valued at $16,647,000 after buying an additional 115,492 shares in the last quarter. Barclays PLC boosted its holdings in InMode by 113.5% in the third quarter. Barclays PLC now owns 169,630 shares of the healthcare company’s stock worth $2,876,000 after acquiring an additional 90,173 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in InMode by 54.1% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,480 shares of the healthcare company’s stock valued at $2,127,000 after acquiring an additional 44,058 shares during the period. Hsbc Holdings PLC increased its holdings in shares of InMode by 129.7% during the second quarter. Hsbc Holdings PLC now owns 90,280 shares of the healthcare company’s stock valued at $1,659,000 after acquiring an additional 50,974 shares in the last quarter. Finally, State Street Corp raised its position in shares of InMode by 3.7% during the third quarter. State Street Corp now owns 2,044,640 shares of the healthcare company’s stock worth $34,657,000 after purchasing an additional 73,183 shares during the period. Institutional investors own 68.04% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on INMD shares. BTIG Research assumed coverage on shares of InMode in a research report on Thursday, October 17th. They issued a “buy” rating and a $25.00 price target for the company. Barclays reduced their price objective on shares of InMode from $29.00 to $27.00 and set an “overweight” rating for the company in a report on Monday, October 14th. Finally, Needham & Company LLC restated a “hold” rating on shares of InMode in a report on Thursday, October 31st. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, InMode presently has an average rating of “Hold” and a consensus target price of $22.60.

InMode Trading Down 8.0 %

Shares of NASDAQ:INMD opened at $16.01 on Thursday. The stock has a market cap of $1.34 billion, a PE ratio of 8.65 and a beta of 2.12. The stock’s fifty day simple moving average is $18.11 and its two-hundred day simple moving average is $17.32. InMode Ltd. has a 1-year low of $14.87 and a 1-year high of $26.80.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.